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litus (T1DM and T2DM,). Prescriptions were costed at UK
£2006 prices from government sources for: insulin, oral hypo-
glycaemic agents (OHAs), glucose monitoring, sharps and deliv-
ery devices and hypoglycaemia rescue medication. RESULTS:
In T1DM, 268 and 625 patients were initiated on detemir 
and glargine respectively, contributing 80 patient years and 282
patient years of treatment. In T2DM, 334 and 977 patients were
initiated respectively, contributing 108 patient years and 384
patient years. In T1DM, the mean total annual cost of diabetes-
related prescriptions was £1518 vs. £1312 (Δ = 14%, p < 0.001)
for detemir and glargine respectively, and £1592 vs. £1113 (Δ =
30%, p < 0.001) in T2DM. The difference in spending for T1DM
and T2DM for detemir with reference to glargine was as follows:
insulin +21% and +37%; OHAs (T2DM only) −24%; glucose
monitoring −1% and 20% and rescue medication +7% and 0%.
CONCLUSIONS: Patients managed with glargine as their basal
insulin generate signiﬁcantly lower prescription costs than those
managed with detemir which translated into a less costly regimen
for both T1DM and T2DM.
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Type 2 diabetes mellitus (DM) and peripheral arterial disease
(PAD) are two very relevant cardiovascular (CV) risk factors,
which can often be found concurrently in the same patient. The
DAVID trial, a double-blind, randomized, aspirin(ASA)-
controlled study, has demonstrated that the use of picotamide, a
thromboxane A2 synthase and receptor dual inhibitor, is associ-
ated with lesser CV morbidity and mortality in this type of
patients in comparison to ASA, considered the standard
antiplatelet agent. OBJECTIVES: To estimate clinical and eco-
nomic impacts of picotamide in the Italian health care setting.
METHODS: We developed a Markov model based on clinical
data from DAVID and national economic parameters and demo-
graphics. RESULTS: The base case scenario, which reﬂects
current prices and reimbursement policy (i.e. ASA fully paid for,
picotamide out-of-pocket for patients) yielded an incremental
cost/effectiveness ratio (ICER) of about 8500 euro/year of life
(YOL) saved, which falls below conventionally adopted willing-
ness to pay thresholds. This cost, however, is totally born by the
patient, while the savings on health care expenditures for
avoided events (and less ASA) beneﬁt the National Health
Service (NHS). These results may help the physician in explain-
ing the consequences of this choice to his/her patients, facilitat-
ing a fully-informed choice. The availability of a theoretical
model allowed to explore some alternative scenarios, that indi-
cate that the ICER can be further lowered and the economical
burden better distributed through policy changes. CONCLU-
SIONS: The pharmacoeconomic model indicated that pico-
tamide is likely to be a cost/effective option for CV mortality and
morbidity prevention in patients with concurrent type 2 DM and
PAD and that the level of adoption of this strategy will depend
on willingness to pay and policy priorities of the NHS and
patients themselves.
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METHODS: A 20-week prospective randomized controlled trial
(RCT), followed by an observational visit (OV) (26–65 weeks
later), using two SMBG methods was undertaken to compare an
integrated glucose meter and electronic logbook (IGMEL) with
conventional meters and paper logbooks (CMPL) in controlling
HbA1c levels. RESULTS: The RCT demonstrated that IGMEL
patients experienced an HbA1c reduction of 0.61% compared
with 0.40% for CMPL patients (p = 0.03). The HbA1c reduction
was coupled with a slight increase in hypoglycemia for IGMEL
(0.21 events/day) compared with CMPL (0.14 events/day), but
a slight increase in monitoring (4.0 vs. 3.5 times/day). At the OV,
those that chose to remain on IGMEL maintained an HbA1c
reduction of 0.5% while those that chose to stay on CMPL
increased HbA1c by 0.2% compared to baseline. These results
were input into a peer-reviewed, validated, economic model pro-
jecting these improvements in HbA1c and hypoglycemia rates
over a patient’s lifetime. Transition probabilities, treatment and
complication costs came from published studies. Costs and clin-
ical outcomes were both discounted at 3% annually. IGMEL was
cost-saving compared with CMPL and improved life expectancy
(0.167 and 0.536 years) and quality-adjusted life expectancy
(0.124 and 0.414 years), based on RCT and OV, respectively.
IGMEL was no longer cost saving when the regimen costs
$122/year and $198/year more than CMPL based on RCT and
OV, respectively. IGMEL remained below $50,000/LE when the
IGMEL regimen was up to $597/year and $1729/year more
expensive than CMPL, based on RCT and OV, respectively.
IGMEL remained below $50,000/QALE when the IGMEL
regimen was up to $477/year and $1378/year more expensive
than CMPL, based on RCT and OV, respectively. CONCLU-
SIONS: The results from this study suggest that over a diabetes
patient’s lifetime, signiﬁcant improvements in LE and QALE will
result and provide strong evidence for economic and patient-
centered value for this integrated blood glucose meter.
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OBJECTIVES: The purpose of this study was to evaluate the rel-
ative cost effectiveness (cost utility) of insulin glargine in the UK
for the treatment of people with Type 1 diabetes mellitus (T1DM)
using pooled data from the Phase III clinical trials programme.
METHODS: This was a health economic evaluation using a sto-
chastic simulation model. Transition probabilities for progression
to diabetes-related complications were derived mainly from the
DCCT (Diabetes Control and Complications Trial). Costs were
derived from published estimates and local data. The maximum
time horizon was 40 years to ensure effective modelling of dia-
betes patients. Utility values were extracted from the Health Out-
comes Data Repository (HODaR) and published sources. Costs
were calculated from UK £2005 prices. Costs and beneﬁts were
discounted annually at 3.5%. In this case, the model reported the
experiences of 1000 subjects averaged over ten repeat simula-
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tions. Relative effectiveness for glycaemic control (HbA1c) and
hypoglycaemia was determined from pivotal clinical trials.
RESULTS: Pooled analysis of pre-registration studies showed no
difference in HbA1c between glargine-treated patients and NPH
but did show a 28% risk reduction in severe hypoglycaemic
episodes and a 22% risk reduction in nocturnal hypoglycaemic
episodes compared to NPH. Over 40 years, treatment with NPH
resulted in 42,518 additional severe hypoglycaemic events and
662,698 additional nocturnal hypoglycaemic events compared to
insulin glargine. The discounted incremental cost effectiveness
ratio (ICER) was £12,302 per quality adjusted life year (QALY)
gained. Sensitivity analyses showed these ﬁndings were robust.
CONCLUSIONS: For any given degree of glycaemia, there was
reduced likelihood of severe and nocturnal hypoglycaemia with
glargine. Insulin glargine is cost-effective when used as basal
insulin for the treatment of people with Type 1 Diabetes. The
ICER is well within accepted thresholds for cost-effective treat-
ments in the UK.
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OBJECTIVES: The 2-year RESULT study demonstrated that
rosiglitazone (RSG) + sulphonylurea (SU) induced a sustained
increase in beta-cell function (BCF) (56%, p < 0.0001) compared
to no change with SU alone (6% p = 0.41). This study explores
the impact of modelling improved BCF on predicted lifetime
health outcomes and health care expenditure in Spain.
METHODS: DiDACT, a peer-reviewed published long-term
model of T2DM, was used to project the natural lifetime pro-
gression of T2DM for 1000 Spanish patients with characteris-
tics matched to those in the RESULT study (73% male, mean
age 68.2 years, mean BMI 30 kg/m2). Following failure to main-
tain glycaemic target (HbA1C ≥ 7.5%) with intermediate dose
of SU, up-titration of SU therapy was compared to RSG + SU
combination. Future costs and outcomes were discounted at 5%
per year. The original calibration of RSG in DiDACT was based
primarily on insulin sensitization. Improved BCF can be repre-
sented by using an additive, multiplicative or combined
approach. The additive representation assumes a one-off change
independent of existing BCF. The multiplicative representation
assumes the impact is proportionate to current BCF. RESULTS:
The ﬁndings demonstrate that both multiplicative and additive
approaches to representing RSG’s effect on BCF result in reduced
lifetime costs and increased Quality Adjusted Life-Years
(QALYs) compared with the previous calibration, with cost-
effectiveness ratios falling well below both established thresholds
and previous estimates. CONCLUSIONS: Each modelling
method of the impact of improved BCF in the management of
T2DM indicated that RSG is more cost-effective than previously
estimated. The impact of RSG on BCF may be conﬁrmed in next
forthcoming long-term studies.
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OBJECTIVES: To examine if close control of blood glucose
levels in patients with type 2 diabetes treated with diet restric-
tions or oral medication has an economic beneﬁt. METHODS:
A decision analytic model with a time horizon of eight years has
been developed. Costs are assessed from the perspective of the
Swiss health care system. Data on the efﬁcacy of SMBG come
from the large observational ROSSO study conducted in
Germany. The economic endpoint is the impact of blood glucose
monitoring on direct medical costs, taking into account reduced
costs due to ﬁve major diabetes-related complications (myocar-
dial infarction (MI), stroke, haemodialysis due to renal failure,
blindness, and foot amputation), and assuming no difference in
all other direct medical costs of diabetes. The clinical endpoint
is quality adjusted life years (QALYs) gained. RESULTS: Self-
monitoring of blood glucose induces a cost saving of CHF1062
over eight years due to a reduction in the number of diabetes-
related complications. This hints at an annual budget saving in
diabetes related complications of CHF21 Mio. per year, based
on an estimate of 160000 non-insulin treated type 2 diabetes
patients in Switzerland. In addition, the quality of life is
improved for patients performing SMBG. A critical parameter is
the number of test strips used. A sensitivity analysis shows that
with a weekly consumption of more than 5.25 strips per patient,
SMBG is no longer a dominant strategy. No related, evidence-
based guidelines are currently available. CONCLUSIONS: The
potential economic beneﬁt of self-monitoring of blood glucose
among non insulin dependent type 2 diabetes patients seems to
be substantial in Switzerland, due to a reduction in long-term
diabetes complications.
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OBJECTIVES: To evaluate lifetime clinical and economic out-
comes in the Swedish setting for patients with type 1 diabetes
treated with either insulin aspart (IAsp) or human soluble insulin
(HSI) as mealtime insulin, based on a multinational clinical trial.
METHODS: A validated diabetes model was used to project
long-term cumulative incidence of complications, life expectancy
(LE), quality-adjusted life expectancy (QALE) and lifetime costs
for IAsp versus HSI. Markov modeling techniques were used to
describe incidence and progression of complications (eye, renal
and cardiovascular disease, and peripheral neuropathy), and
Monte Carlo simulation accounted for uncertainty. Probabilities
of complications and HbA1c-dependent adjustments were
derived from landmark clinical and epidemiological studies.
Cohort deﬁnition and intervention effects were taken from a 30-
month multicenter, multinational, open-labeled phase III exten-
sion trial in patients with type 1 diabetes. Costs were retrieved
from published sources and expressed in 2005 Swedish Kronor
(SEK) from a societal perspective (human capital approach). LE,
QALE and total costs were projected over a 50-year time horizon
and discounted at 3% per annum. RESULTS: IAsp was associ-
ated with an increase in LE of 0.13 years (16.38 ± 0.17 versus
16.26 ± 0.17) and in QALE of 0.14 quality-adjusted life years
(QALYs) (10.86 ± 0.11 versus 10.72 ± 0.11) compared to HSI.
The cumulative incidence of most diabetes-related complications
was estimated to be lower for IAsp versus HSI. Long-term direct
costs were slightly higher with IAsp than with HSI (SEK 568,532
